Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis.

Yoshida Y, Joshi P, Barri S, Wang J, Corder AL, O'Connell SS, Fonseca VA

Journal of diabetes and its complications5 Jul 2022Cited by 51 (Europe PMC)

PMID35817678DOI10.1016/j.jdiacomp.2022.108255PepBankPUB-35817678

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, pooled GLP1 RAs (including liraglutide) were associated with an elevated risk of rapidly worsening diabetic retinopathy in four major RCTs with cardiovascular benefits (OR 1.23).
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs such as liraglutide were linked to a higher risk of fast-worsening eye disease in four trials.
Peptide
Liraglutide
Outcome
IncreaseRapidly worsening diabetic retinopathy in RCTs with cardiovascular benefits
Study
n: not reported in source
Outcome group
Adverse events · Eye
Measurements
OR
1.23 NA
rapidly worsening DR, 4 RCTs with CV benefits
Source sentences
Summary
GLP1RA was associated with an elevated risk of rapidly worsening DR in four major RCTs with CV benefits in T2DM (OR 1.23, 95 % CI 1.05-1.44).
1 context sentence(design, population, supporting numbers)
Summary · context
We included 13 RCTs examining the effect of GLP1 RA on health outcomes/adverse events including DR or DR complications in T2DM.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3581767801
02HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, the association of pooled GLP1 RAs with diabetic retinopathy was significant in RCTs longer than 52 weeks (OR 1.2).
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs were linked to more diabetic eye disease in trials longer than 52 weeks.
Peptide
Liraglutide
Outcome
IncreaseRapidly worsening diabetic retinopathy in RCTs longer than 52 weeks
Study
n: not reported in source
Outcome group
Adverse events · Eye
Measurements
OR
1.2 NA
RCTs over 52 weeks
Source sentences
Summary
The association between GLP1 RA and DR was significant in subgroups of RCTs with length over 52 weeks (1.2, 1.00-1.43), using placebo as a comparator (1.22, 1.05-1.42).
1 context sentence(design, population, supporting numbers)
Summary · context
We included 13 RCTs examining the effect of GLP1 RA on health outcomes/adverse events including DR or DR complications in T2DM.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3581767802
03HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, the association of pooled GLP1 RAs with diabetic retinopathy was significant in RCTs using placebo as comparator (OR 1.22).
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs were linked to more diabetic eye disease than placebo in placebo-controlled trials.
Peptide
Liraglutide
Outcome
IncreaseRapidly worsening diabetic retinopathy in placebo-controlled RCTs
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Eye
Measurements
OR
1.22 NA
RCTs with placebo comparator
Source sentences
Summary
The association between GLP1 RA and DR was significant in subgroups of RCTs with length over 52 weeks (1.2, 1.00-1.43), using placebo as a comparator (1.22, 1.05-1.42).
1 context sentence(design, population, supporting numbers)
Summary · context
We included 13 RCTs examining the effect of GLP1 RA on health outcomes/adverse events including DR or DR complications in T2DM.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3581767803
04HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes for 10 years or more, the association of pooled GLP1 RAs with diabetic retinopathy did not reach statistical significance (OR 1.19).
In plain wordsIn adults with long-standing type 2 diabetes, the link between GLP-1 drugs and diabetic eye disease was not statistically significant.
Peptide
Liraglutide
Outcome
No significant changeDiabetic retinopathy in patients with T2DM for 10 years or more
Study
n: not reported in source
Outcome group
Adverse events · Eye
Measurements
OR
1.19 NA
T2DM 10 years or more
Source sentences
Summary
In subgroups with patients who had T2DM ≥10 years (1.19, 0.99-1.42) or with subjects enrolled from multiple countries (1.2, 0.99-1.46), the association appeared to be evident but did not reach statistical significance.
1 context sentence(design, population, supporting numbers)
Summary · context
We included 13 RCTs examining the effect of GLP1 RA on health outcomes/adverse events including DR or DR complications in T2DM.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3581767804
05HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In RCTs with subjects from multiple countries, the association of pooled GLP1 RAs with diabetic retinopathy did not reach statistical significance (OR 1.2).
In plain wordsIn trials with people from several countries, the link between GLP-1 drugs and diabetic eye disease was not statistically significant.
Peptide
Liraglutide
Outcome
No significant changeDiabetic retinopathy in multinational RCTs
Study
n: not reported in source
Outcome group
Adverse events · Eye
Measurements
OR
1.2 NA
RCTs with subjects from multiple countries
Source sentences
Summary
In subgroups with patients who had T2DM ≥10 years (1.19, 0.99-1.42) or with subjects enrolled from multiple countries (1.2, 0.99-1.46), the association appeared to be evident but did not reach statistical significance.
1 context sentence(design, population, supporting numbers)
Summary · context
We included 13 RCTs examining the effect of GLP1 RA on health outcomes/adverse events including DR or DR complications in T2DM.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3581767805
06HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (including semaglutide) were linked to a higher risk of rapidly worsening diabetic retinopathy in four major trials with cardiovascular benefit.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group were linked to a higher risk of fast-worsening eye disease.
Peptide
Semaglutide
Outcome
IncreaseRapidly worsening diabetic retinopathy in RCTs with cardiovascular benefits
Study
n: not reported in source
Outcome group
Vision and retina · Eye
Measurements
Odds ratio
1.23
four RCTs with CV benefits
Source sentences
Summary
GLP1RA was associated with an elevated risk of rapidly worsening DR in four major RCTs with CV benefits in T2DM (OR 1.23, 95 % CI 1.05-1.44).
1 context sentence(design, population, supporting numbers)
Summary · context
We included 13 RCTs examining the effect of GLP1 RA on health outcomes/adverse events including DR or DR complications in T2DM.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3581767806
07HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, the pooled GLP-1 receptor agonist association with diabetic retinopathy was significant in trials longer than 52 weeks.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group were linked to more eye disease worsening in longer trials.
Peptide
Semaglutide
Outcome
IncreaseDiabetic retinopathy, subgroup of trials longer than 52 weeks
Study
n: not reported in source
Outcome group
Vision and retina · Eye
Measurements
Odds ratio
1.2
trials over 52 weeks
Source sentences
Summary
The association between GLP1 RA and DR was significant in subgroups of RCTs with length over 52 weeks (1.2, 1.00-1.43), using placebo as a comparator (1.22, 1.05-1.42).
1 context sentence(design, population, supporting numbers)
Summary · context
We included 13 RCTs examining the effect of GLP1 RA on health outcomes/adverse events including DR or DR complications in T2DM.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3581767807
08HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, the pooled GLP-1 receptor agonist association with diabetic retinopathy was significant in trials that used placebo as comparator.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group were linked to more eye disease worsening in placebo-controlled trials.
Peptide
Semaglutide
Outcome
IncreaseDiabetic retinopathy, subgroup of placebo-controlled trials
Study
n: not reported in source
Comparator
Placebo
Outcome group
Vision and retina · Eye
Measurements
Odds ratio
1.22
placebo comparator trials
Source sentences
Summary
using placebo as a comparator (1.22, 1.05-1.42).
1 context sentence(design, population, supporting numbers)
Summary · context
We included 13 RCTs examining the effect of GLP1 RA on health outcomes/adverse events including DR or DR complications in T2DM.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3581767808
09HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes of at least 10 years, the pooled GLP-1 receptor agonist association with diabetic retinopathy did not reach statistical significance.
In plain wordsIn people with long-standing type 2 diabetes, GLP-1 drugs as a group were not clearly linked to more eye disease worsening.
Peptide
Semaglutide
Outcome
No significant changeDiabetic retinopathy, subgroup with diabetes of 10 years or longer
Study
n: not reported in source
Outcome group
Vision and retina · Eye
Measurements
Odds ratio
1.19
T2DM 10 years or longer
Source sentences
Summary
In subgroups with patients who had T2DM ≥10 years (1.19, 0.99-1.42)
1 context sentence(design, population, supporting numbers)
Summary · context
We included 13 RCTs examining the effect of GLP1 RA on health outcomes/adverse events including DR or DR complications in T2DM.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3581767809
10HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes in multinational trials, the pooled GLP-1 receptor agonist association with diabetic retinopathy did not reach statistical significance.
In plain wordsIn multinational trials, GLP-1 drugs as a group were not clearly linked to more eye disease worsening.
Peptide
Semaglutide
Outcome
No significant changeDiabetic retinopathy, subgroup of multinational trials
Study
n: not reported in source
Outcome group
Vision and retina · Eye
Measurements
Odds ratio
1.2
multinational trials
Source sentences
Summary
or with subjects enrolled from multiple countries (1.2, 0.99-1.46), the association appeared to be evident but did not reach statistical significance
1 context sentence(design, population, supporting numbers)
Summary · context
We included 13 RCTs examining the effect of GLP1 RA on health outcomes/adverse events including DR or DR complications in T2DM.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3581767810

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 3 to 38Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis.

Summary

Results from this study10

Studies that did not test the peptide alone10

Version history

Subjects

Publication types

MeSH terms

Keywords